GenSight will participate to the 2020 Virtual Annual Meeting of the American Society for Retina Specialists (ASRS) from 24-26 July 2020.
One e-poster will present GS030, our lead gene therapy product candidate, an innovative optogenetic treatment that started a Phase I/II PIONEER clinical trial in Europe and US with patients affected by Retinitis Pigmentosa (RP).
GS030 – Optogenetics in Retinitis Pigmentosa (RP)
Title – Optogenetics in the Clinic: PIONEER, a Phase 1/2 Gene Therapy Program for Non-Syndromic Retinitis Pigmentosa
- E-Scientific poster
- Poster Author: Joseph Martel, MD, Assistant Professor of Ophthalmology Retina and Vitreous Servious, UPMC Eye Center – Eye & Ear Institute, Pittsburg, PA (US)